Finland· FI-REL-REL57530
Bumacor
A butylscopolamine product containing hyoscine butylbromide, registered in Finland by Macure Pharma ApS. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Butylscopolamine is registered in 11 of 19 countries.
Countries holding a registration under ATC A03BB01 (butylscopolamine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Butylscopolamine · ATC A03BB01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Hyoscine butylbromide
- Manufacturer
- Macure Pharma ApS
- Country
- Finland (FI)
- ATC code
- A03BB01
- ATC class
- Butylscopolamine
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Butylscopolamine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomBuscopan 10mg tabletsLexon (UK) Ltd
- BelgiumBuscafor 10 mg - 500 mgUPSA
- GermanyBuscopanA. Nattermann & Cie. Gmbh
- SwedenBumacor 20 mg/ml Injektionsvätska, lösningMACURE PHARMA ApS
- CzechiaBUSCOPANMayoly Pharma France, Rueil-Malmaison
- NetherlandsBuscopan, injectievloeistof 20 mg/mlEuro Registratie Collectief B.V.
- NorwayBumacorMacure Pharma ApS
- CanadaACCEL-HYOSCINEACCEL PHARMA INC
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Buscapina, Buscopan
- Belgium · Buscopan, Buscopan Forte
- Bulgaria · Бусколизин, Бусколизин Форте
- Cyprus · Avotrin, Buscopan
- Czechia · Buscopan, Butylskopolaminium Bromid Kalceks
- Germany · Buscopan, Buscopan Ampullen
- Denmark · Bumacor
- Estonia · Bysimin
- Spain · Buscapina, Buscopresc
- France · Buscopan, Scoburen
- United Kingdom (Northern Ireland) · Almus Ibs Relief, Almus Stomach Cramp Relief
- Greece · Avotrin, Buscopan
- Croatia · Buscopan, Bysimin
- Hungary · Buscopan, Buscopan Forte
- Ireland · Buscopan, Buscopan Ampoules
- Italy · Addofix, Buscopan
- Luxembourg · Buscopan, Buscopan Forte
- Latvia · Buscopan, Hyoscine Butylbromide Kalceks
- Malta · Buscopan, Buscopan Ampoules
- Netherlands · Buscopan, Scopolamine Butylbromide Kalceks
- Norway · Bumacor, Buscopan
- Poland · Aurogastro, Buscolysin
- Portugal · Buscopan, Butilescopolamina Conforpam
- Romania · Buscopan, Buscotil
- Sweden · Bumacor, Buscopan
- Slovenia · Buscopan
- Slovakia · Buscopan, Scopolamine Butylbromide Kalceks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa047270-4c88-4f29-8eb1-8e48cf6117b2 GET /v1/drugs/fa047270-4c88-4f29-8eb1-8e48cf6117b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "60",
"form": "injektioneste, liuos",
"route": "Ihon alle",
"ddd_unit": "mg",
"strength": "20 mg/ml",
"atc_label": "butyyliskopolamiini",
"ma_number": "38469",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL57530",
"authorised_at": "2022-09-05"
}See everything about butylscopolamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.